U.S. Kidney Stones Market Size, Share & Forecast 2026–2032

ID: MR-11866 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Kidney Stones Market
  • ✓Market Size 2024: USD 2.1 billion
  • ✓Market Size 2032: USD 3.0 billion
  • ✓CAGR: 4.6%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Outpatient Migration Reshaping Volumes: Medicare's ASC payment rules are shifting ureteroscopy volumes from hospital outpatient departments to freestanding facilities. Boston Scientific and Olympus are tailoring single-use scope portfolios to ASC economics, since disposables remove reprocessing costs.
FINDING 02
Shockwave Lithotripsy Persistence: Many assume shockwave lithotripsy is being displaced entirely by ureteroscopy. Under CPT 50590 reimbursement, ESWL remains the lowest-cost option for small uncomplicated stones, and Dornier MedTech's installed base will sustain demand through 2032.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Multi-Year Contracts: Hospital procurement teams and ASC operators should negotiate multi-year single-use ureteroscope contracts before the CY2026 OPPS rule takes effect on January 1, 2026, because reimbursement shifts will compress per-procedure margins across facility types.

U.S. Kidney Stone Care: Market Overview

The U.S. kidney stones market, spanning ureteroscopy, shockwave lithotripsy, percutaneous nephrolithotomy, and prescription prevention therapy, was valued at USD 2.1 billion in 2024. NIDDK data indicate that roughly one in eleven Americans will develop a kidney stone, and the Centers for Disease Control and Prevention links rising incidence to obesity and type 2 diabetes. Demand is therefore anchored in a large, recurring patient base rather than discretionary elective surgery, which gives reimbursement policy outsized influence over market value.

Market structure reflects a hybrid model in which government sets the economics and private firms drive the technology. The Centers for Medicare and Medicaid Services (CMS) publishes annual Physician Fee Schedule values and Hospital Outpatient Prospective Payment System rates that determine procedure profitability for urology practices and hospitals. Private manufacturers, led by Boston Scientific, Olympus Corporation of the Americas, and Karl Storz Endoscopy America, have driven innovation in single-use ureteroscopes and access sheaths, while government dominates only pricing and coverage decisions.

Policy-Driven Growth in U.S. Kidney Stone Care

The Inflation Reduction Act of 2022 (Public Law 117-169) is the most consequential demand driver for prevention therapy. Its Medicare Part D redesign caps annual beneficiary out-of-pocket spending at USD 2,000 from 2025, removing the cost barrier that previously interrupted long-term potassium citrate and thiazide regimens. Because recurrence affects roughly half of patients within ten years of a first episode, sustained adherence converts episodic procedure demand into recurring prescription volume across the Medicare population.

CMS coverage rules create the second and third mechanisms. The CMS Ambulatory Surgical Center Covered Procedures List determines which urolithiasis procedures ASCs can bill under Medicare, and each annual update moves ureteroscopy volume from hospital outpatient departments into lower-cost settings. Separately, CPT 52356, which describes ureteroscopy with lithotripsy, and CPT 50590 for extracorporeal shockwave lithotripsy are valued through the annual Physician Fee Schedule, so each revaluation directly alters procedure throughput and capital equipment purchasing decisions.

Regulatory Barriers and Compliance Costs

The FDA's Center for Devices and Radiological Health (CDRH) administers premarket review for urological devices. Ureteroscopes and access sheaths typically follow the 510(k) pathway under 21 CFR Part 807, with a MDUFA performance goal of 90 FDA days for decisions, while shockwave lithotripters require premarket approval under 21 CFR Part 814 with a 180-day review goal. From February 2, 2026, the Quality Management System Regulation under 21 CFR Part 820 aligns manufacturers with ISO 13485, adding documentation and audit costs for every device line.

Market access also depends on price transparency and state licensing. Hospitals must publish standard charges under the Hospital Price Transparency requirements in 45 CFR Part 180, administered by CMS, and face civil monetary penalties for noncompliance. States including New York and North Carolina administer certificate of need programmes that require state health department approval before an ASC adds lithotripsy or ureteroscopy capacity, adding delays commonly measured in months.

Policy-Created Opportunities in the United States

The Part D out-of-pocket cap creates an opportunity for pharmacy-led adherence programmes targeting generic potassium citrate and thiazide prophylaxis. Under the Medicare Prescription Payment Plan, enrolled beneficiaries spread out-of-pocket costs across monthly payments, and pharmacy benefit managers and specialty urology networks can capture this demand by enrolling recurrent stone formers in structured follow-up programmes. Mission Pharmacal and Viatris are positioned to supply high-volume potassium citrate and generic formulations to these programmes.

The CMS ASC Covered Procedures List creates a second opportunity for freestanding surgical centers to acquire single-use ureteroscopy and lithotripsy capacity. Operators that secure ASC-certified facilities before the CY2026 OPPS rule takes effect on January 1, 2026 gain payment-rate stability relative to hospital outpatient departments. Meanwhile, HRSA's 340B Drug Pricing Program allows qualifying safety-net and urology hospitals to purchase prevention drugs at discounted prices, creating procurement opportunities for generic distributors serving covered entities.

Regulatory and Policy Environment

The primary legislation governing this market is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), which defines device classification and premarket pathways, and Title XVIII of the Social Security Act, which governs Medicare payment for urological services. The Inflation Reduction Act of 2022 (Public Law 117-169) layers drug pricing and Part D benefit redesign onto this framework. Responsible agencies are the FDA's CDRH for devices, CMS for reimbursement and price transparency, and HRSA for 340B administration, with key compliance requirements including 510(k) or PMA clearance, QMSR conformity from February 2, 2026, and Hospital Price Transparency postings under 45 CFR Part 180.

Upcoming changes include the CY2026 OPPS final rule effective January 1, 2026, the MDUFA V reauthorization process ahead of the program's September 30, 2027 expiry, and annual indexing of the USD 2,000 Part D cap. Compared with regional peers, the U.S. framework offers faster device clearance than the EU Medical Device Regulation (Regulation (EU) 2017/745), which requires notified body certification for Class IIa devices, while Canada's Medical Devices Regulations (SOR/98-282) run through Health Canada with provincially funded procedures under the Canada Health Act. Reimbursement remains more fragmented in the U.S. than in either peer.

Long-Term Policy Outlook for U.S. Kidney Stone Care

By 2032, the most significant policy shift will be the migration of urological procedures toward site-neutral payment structures. CMS has proposed site-neutral policies for selected outpatient services, and each successive OPPS rulemaking narrows the reimbursement gap between hospital outpatient departments and freestanding ASCs. This will compress hospital margins on ureteroscopy and redirect capital investment toward ASCs and office-based lithotripsy units.

Drug pricing reform will extend beyond the first Medicare negotiated drugs as the Inflation Reduction Act's negotiation programme phases in Part B drugs from 2028, reshaping the economics of injectable therapies used in complicated stone management. Generic potassium citrate and thiazides will remain outside negotiation pressure, preserving volume for generic manufacturers through 2032. FDA cybersecurity expectations under Section 524B of the Federal Food, Drug, and Cosmetic Act will add compliance cost to connected ureteroscopes and lithotripters.

Frequently Asked Questions

The Inflation Reduction Act caps Part D out-of-pocket spending at USD 2,000 from 2025, reducing cost barriers to long-term potassium citrate and thiazide therapy. This allows recurrent stone formers to maintain prophylaxis without interruption.
Ureteroscopes and access sheaths generally follow the 510(k) pathway under 21 CFR Part 807, with a 90 FDA-day review goal. Shockwave lithotripters require premarket approval under 21 CFR Part 814, with a 180-day review goal.
The Quality Management System Regulation under 21 CFR Part 820 takes effect on February 2, 2026. It aligns manufacturer quality systems with ISO 13485 and adds audit and documentation requirements.
Hospitals must publish standard charges for urological procedures under 45 CFR Part 180, administered by CMS. Noncompliance exposes hospitals to civil monetary penalties.
Site-neutral proposals narrow the payment gap between hospital outpatient departments and freestanding ASCs. This shift redirects ureteroscopy and lithotripsy volume toward lower-cost surgical settings.

Market Segmentation

By Treatment Modality
  • Ureteroscopy
  • Shockwave Lithotripsy
  • Percutaneous Nephrolithotomy
  • Medical Expulsive Therapy
  • Pharmacological Prophylaxis
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Office-Based Urology Practices
  • Diagnostic Imaging Centers
By Payer
  • Medicare
  • Medicaid
  • Commercial Insurance
  • Self-Pay Patients

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 Kidney Stone Care in the U.S. - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Treatment Modality Insights
4.1 Ureteroscopy
4.2 Shockwave Lithotripsy
4.3 Percutaneous Nephrolithotomy
4.4 Medical Expulsive Therapy
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Ambulatory Surgical Centers
5.3 Office-Based Urology Practices
5.4 Others
Chapter 06 Payer Insights
6.1 Medicare
6.2 Medicaid
6.3 Commercial Insurance
6.4 Self-Pay Patients
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Boston Scientific Corporation
7.2.2 Olympus Corporation of the Americas
7.2.3 Karl Storz Endoscopy America
7.2.4 Cook Medical
7.2.5 Teleflex Incorporated
7.2.6 Dornier MedTech America
7.2.7 Richard Wolf Medical Instruments Corporation
7.2.8 Becton, Dickinson and Company
7.2.9 Viatris Inc.
7.2.10 Mission Pharmacal Company
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.